RPG Life Sciences Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
2027.10 -16.25 (-0.80%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2025.05
Today’s High
2075.95
52 Week Low
1290.3
52 Week High
2976.7
2032.00 -14.00 (-0.68%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2013
Today’s High
2077.5
52 Week Low
1292
52 Week High
2974.95
Key Metrics
- Market Cap (In Cr) 3383.88
- Beta 1.07
- Div. Yield (%) 0.78
- P/B 9.03
- TTM P/E 55.11
- Peg Ratio 1.6
- Sector P/E 31.15
- D/E 0
- Open Price 2050
- Prev Close 2043.35
RPG Life Sciences Analysis
Price Analysis
-
1 Week-12.72%
-
3 Months-2.93%
-
6 Month38.18%
-
YTD53.16%
-
1 Year43.75%
Risk Meter
- 47% Low risk
- 47% Moderate risk
- 47% Balanced Risk
- 47% High risk
- 47% Extreme risk
RPG Life Sciences News
Breakout stocks to buy or sell: Sumeet Bagadia recommends 5 shares to buy today
2 min read . 09 Aug 2024Multibagger pharma stock up over 230% in 3 years, Board declares 150% dividend
3 min read . 29 Apr 2023With 3-year CAGR return of 33%, this pharma stock sets record date for dividend
2 min read . 02 Jul 2022Stocks to Watch: Maruti, Axis Bank, Vodafone Idea, IEX, Deepak Nitrite
3 min read . 25 Jan 2022RPG Life Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 582.05
- Selling/ General/ Admin Expenses Total
- 132.15
- Depreciation/ Amortization
- 17.07
- Other Operating Expenses Total
- 137.22
- Total Operating Expense
- 470.97
- Operating Income
- 111.08
- Net Income Before Taxes
- 117.84
- Net Income
- 87.66
- Diluted Normalized EPS
- 53.01
- Period
- 2024
- Total Assets
- 512.87
- Total Liabilities
- 138.02
- Total Equity
- 374.85
- Tangible Book Valueper Share Common Eq
- 209.7
- Period
- 2024
- Cashfrom Operating Activities
- 94.36
- Cashfrom Investing Activities
- -79.15
- Cashfrom Financing Activities
- -20.31
- Net Changein Cash
- -5.1
- Period
- 2023
- Total Revenue
- 512.81
- Selling/ General/ Admin Expenses Total
- 224.82
- Depreciation/ Amortization
- 15.5
- Total Operating Expense
- 424.84
- Operating Income
- 87.97
- Net Income Before Taxes
- 91.68
- Net Income
- 67.64
- Diluted Normalized EPS
- 41.25
- Period
- 2023
- Total Assets
- 419.35
- Total Liabilities
- 111.75
- Total Equity
- 307.6
- Tangible Book Valueper Share Common Eq
- 165.79
- Period
- 2023
- Cashfrom Operating Activities
- 90.81
- Cashfrom Investing Activities
- -105.81
- Cashfrom Financing Activities
- -17.12
- Net Changein Cash
- -32.12
- Period
- 2022
- Total Revenue
- 440.16
- Selling/ General/ Admin Expenses Total
- 187.1
- Depreciation/ Amortization
- 15.66
- Other Operating Expenses Total
- 3.8
- Total Operating Expense
- 369.46
- Operating Income
- 70.7
- Net Income Before Taxes
- 73.17
- Net Income
- 51.48
- Diluted Normalized EPS
- 31.13
- Period
- 2022
- Total Assets
- 344.61
- Total Liabilities
- 88.84
- Total Equity
- 255.77
- Tangible Book Valueper Share Common Eq
- 133.68
- Period
- 2022
- Cashfrom Operating Activities
- 64.75
- Cashfrom Investing Activities
- -34.66
- Cashfrom Financing Activities
- -13.51
- Net Changein Cash
- 16.58
- Period
- 2021
- Total Revenue
- 389.14
- Selling/ General/ Admin Expenses Total
- 158.19
- Depreciation/ Amortization
- 16.47
- Other Operating Expenses Total
- 12.1
- Total Operating Expense
- 335.67
- Operating Income
- 53.47
- Net Income Before Taxes
- 53.58
- Net Income
- 40
- Diluted Normalized EPS
- 24.19
- Period
- 2021
- Total Assets
- 303.39
- Total Liabilities
- 86.94
- Total Equity
- 216.45
- Tangible Book Valueper Share Common Eq
- 108.42
- Period
- 2021
- Cashfrom Operating Activities
- 58.27
- Cashfrom Investing Activities
- -7.96
- Cashfrom Financing Activities
- -10.49
- Net Changein Cash
- 39.82
- Period
- 2020
- Total Revenue
- 375.57
- Selling/ General/ Admin Expenses Total
- 160.89
- Depreciation/ Amortization
- 16.36
- Other Operating Expenses Total
- 9.2
- Total Operating Expense
- 337.99
- Operating Income
- 37.58
- Net Income Before Taxes
- 36.45
- Net Income
- 29.01
- Diluted Normalized EPS
- 20.15
- Period
- 2020
- Total Assets
- 266.73
- Total Liabilities
- 90.16
- Total Equity
- 176.57
- Tangible Book Valueper Share Common Eq
- 81.44
- Period
- 2020
- Cashfrom Operating Activities
- 50.17
- Cashfrom Investing Activities
- -10.7
- Cashfrom Financing Activities
- -39.3
- Net Changein Cash
- 0.17
- Period
- 2019
- Total Revenue
- 330.16
- Selling/ General/ Admin Expenses Total
- 158.95
- Depreciation/ Amortization
- 15.32
- Other Operating Expenses Total
- 10.53
- Total Operating Expense
- 311.86
- Operating Income
- 18.3
- Net Income Before Taxes
- 15.05
- Net Income
- 10.81
- Diluted Normalized EPS
- 6.56
- Period
- 2019
- Total Assets
- 251.24
- Total Liabilities
- 90.74
- Total Equity
- 160.5
- Tangible Book Valueper Share Common Eq
- 65.49
- Period
- 2019
- Cashfrom Operating Activities
- 45.78
- Cashfrom Investing Activities
- -19.02
- Cashfrom Financing Activities
- -26.5
- Net Changein Cash
- 0.26
- Period
- 2024-09-30
- Total Revenue
- 172.21
- Selling/ General/ Admin Expenses Total
- 33.09
- Depreciation/ Amortization
- 5.31
- Other Operating Expenses Total
- 39.02
- Total Operating Expense
- 158.89
- Operating Income
- 13.32
- Net Income Before Taxes
- 15.09
- Net Income
- 4.2
- Diluted Normalized EPS
- 13.27
- Period
- 2024-09-30
- Total Assets
- 554.37
- Total Liabilities
- 174.99
- Total Equity
- 379.38
- Tangible Book Valueper Share Common Eq
- 213.84
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 46.33
- Cashfrom Investing Activities
- -21.99
- Cashfrom Financing Activities
- -26.78
- Net Changein Cash
- -2.44
- Period
- 2024-06-30
- Total Revenue
- 165.42
- Selling/ General/ Admin Expenses Total
- 32.74
- Depreciation/ Amortization
- 5.29
- Other Operating Expenses Total
- 38.6
- Total Operating Expense
- 131.64
- Operating Income
- 33.78
- Net Income Before Taxes
- 36
- Net Income
- 26.76
- Diluted Normalized EPS
- 16.18
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 126.99
- Selling/ General/ Admin Expenses Total
- 32.08
- Depreciation/ Amortization
- 4.49
- Other Operating Expenses Total
- 32.75
- Total Operating Expense
- 110.76
- Operating Income
- 16.23
- Net Income Before Taxes
- 17.74
- Net Income
- 13.24
- Diluted Normalized EPS
- 8.01
- Period
- 2024-03-31
- Total Assets
- 512.87
- Total Liabilities
- 138.02
- Total Equity
- 374.85
- Tangible Book Valueper Share Common Eq
- 209.7
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 94.36
- Cashfrom Investing Activities
- -79.15
- Cashfrom Financing Activities
- -20.31
- Net Changein Cash
- -5.1
- Period
- 2023-12-31
- Total Revenue
- 153.7
- Selling/ General/ Admin Expenses Total
- 33.69
- Depreciation/ Amortization
- 4.14
- Other Operating Expenses Total
- 33.94
- Total Operating Expense
- 119.94
- Operating Income
- 33.76
- Net Income Before Taxes
- 35.54
- Net Income
- 26.46
- Diluted Normalized EPS
- 16
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 153.58
- Selling/ General/ Admin Expenses Total
- 33.59
- Depreciation/ Amortization
- 4.23
- Other Operating Expenses Total
- 37.96
- Total Operating Expense
- 120.52
- Operating Income
- 33.06
- Net Income Before Taxes
- 34.79
- Net Income
- 25.86
- Diluted Normalized EPS
- 15.64
- Period
- 2023-09-30
- Total Assets
- 461.14
- Total Liabilities
- 125.4
- Total Equity
- 335.74
- Tangible Book Valueper Share Common Eq
- 184.79
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 34.24
- Cashfrom Investing Activities
- -16.8
- Cashfrom Financing Activities
- -19.94
- Net Changein Cash
- -2.5
- Period
- 2023-06-30
- Total Revenue
- 147.78
- Selling/ General/ Admin Expenses Total
- 32.79
- Depreciation/ Amortization
- 4.21
- Other Operating Expenses Total
- 32.57
- Total Operating Expense
- 119.75
- Operating Income
- 28.03
- Net Income Before Taxes
- 29.77
- Net Income
- 22.1
- Diluted Normalized EPS
- 13.36
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 118.49
- Selling/ General/ Admin Expenses Total
- 33.77
- Depreciation/ Amortization
- 3.89
- Other Operating Expenses Total
- 29.32
- Total Operating Expense
- 106.47
- Operating Income
- 12.02
- Net Income Before Taxes
- 13.81
- Net Income
- 10.35
- Diluted Normalized EPS
- 6.26
- Period
- 2023-03-31
- Total Assets
- 419.35
- Total Liabilities
- 111.75
- Total Equity
- 307.6
- Tangible Book Valueper Share Common Eq
- 165.79
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 90.81
- Cashfrom Investing Activities
- -105.81
- Cashfrom Financing Activities
- -17.12
- Net Changein Cash
- -32.12
- Period
- 2022-12-31
- Total Revenue
- 130.6
- Selling/ General/ Admin Expenses Total
- 28.29
- Depreciation/ Amortization
- 3.91
- Other Operating Expenses Total
- 30.63
- Total Operating Expense
- 105.3
- Operating Income
- 25.3
- Net Income Before Taxes
- 25.74
- Net Income
- 19.11
- Diluted Normalized EPS
- 11.56
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
RPG Life Sciences Technical
Moving Average
SMA
- 5 Day2140.34
- 10 Day2349.33
- 20 Day2424.65
- 50 Day2459.2
- 100 Day2181.11
- 300 Day1853.37
RPG Life Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Gujarat Themis Biosyn
- 317.95
- -10
- -3.05
- 390
- 108.2
- 2309.7
- Dishman Carbogen Amcis
- 218.15
- -2.4
- -1.09
- 282.95
- 132.75
- 3420.22
- RPG Life Sciences
- 2027.1
- -16.25
- -0.8
- 2976.7
- 1290.3
- 3352.62
- Alembic
- 123.8
- -1.4
- -1.12
- 169
- 78.2
- 3179.18
- Indoco Remedies
- 299.5
- -4.8
- -1.58
- 416.95
- 286.5
- 2761.39
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Gujarat Themis Biosyn
- 60.4
- 17.75
- 45.22
- 35.22
- Dishman Carbogen Amcis
- -
- 0.61
- -0.61
- -1.54
- RPG Life Sciences
- 38.61
- 9.03
- 22.53
- 11.99
- Alembic
- 11.98
- 1.47
- 13.55
- 71.82
- Indoco Remedies
- 31.02
- 2.53
- 12.02
- 6.93
RPG Life Sciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-24
- Quarterly Results
- 19-Jul-24
- Quarterly Results
- 30-Apr-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 18-Oct-23
- Quarterly Results
- 28-Jul-23
- Quarterly Results
- 28-Apr-23
- Audited Results & Final Dividend
- 01-Feb-23
- Quarterly Results
- 17-Oct-22
- Quarterly Results
- 02-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 16-Jul-24
- 11-Jun-24
- AGM
- 09-Mar-24
- 07-Feb-24
- POM
- 04-Aug-23
- 28-Apr-23
- AGM
- 29-Jul-22
- 04-Jul-22
- AGM
- 31-Aug-21
- 09-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-Apr-24
- 28-Jun-24
- 28-Jun-24
- 16
- 28-Apr-23
- 21-Jul-23
- 21-Jul-23
- 12
- 29-Apr-22
- 15-Jul-22
- 14-Jul-22
- 9.6
- 30-Apr-21
- 17-Aug-21
- 13-Aug-21
- 7.2